The Centers for Medicare & Medicaid Services is celebrating the 10th anniversary of Part D by proposing the most sweeping changes to the Medicare drug benefit since it launched. Proposed revisions to the “Protected Classes” will get the most attention, but the rest of the rule may have more profound impacts going forward.
The Part D program is all grown up.
That, at least, is how the Centers for Medicare & Medicaid Services sees it. In a proposed rule
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.
An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.
The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.
For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.
Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
The state's Prescription Drug Affordability Board, the oldest of a growing list of the boards, chose six drugs for affordability reviews and has the authority to set a ceiling on the amount state and local government payers would reimburse for them.
